Trials / Completed
CompletedNCT03643484
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy
IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Locally Advanced Unresectable Non-small Cell Lung Cancer Who Are Treated With Maintenance Therapy After Definitive Chemoradiation Therapy.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 634 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in patients with locally advanced unresectable non-small cell lung cancer who are treated with the product as maintenance therapy after definitive chemoradiation therapy.
Conditions
Timeline
- Start date
- 2018-10-24
- Primary completion
- 2021-06-30
- Completion
- 2021-06-30
- First posted
- 2018-08-22
- Last updated
- 2024-02-21
Locations
37 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03643484. Inclusion in this directory is not an endorsement.